Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
78,024,641
-
Total 13F shares
-
41,781,497
-
Share change
-
+5,508,366
-
Total reported value
-
$167,123,225
-
Put/Call ratio
-
230%
-
Price per share
-
$4.00
-
Number of holders
-
92
-
Value change
-
+$27,653,733
-
Number of buys
-
64
-
Number of sells
-
38
Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (CRVS) as of Q2 2025
As of 30 Jun 2025,
Corvus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (CRVS) was held by
92 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
41,781,497 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Point72 Asset Management, L.P., BlackRock, Inc., VANGUARD GROUP INC, ADAMS STREET PARTNERS LLC, RTW INVESTMENTS, LP, Vivo Capital, LLC, Foresite Capital Management VI LLC, PERCEPTIVE ADVISORS LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
92
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.